Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	gastric cancer
ICD-0-3	C16
Methods	RNA-seq, qPCR, Western blot, in vitro knockdown
Sample	gastric cancer tissues, cell lines (AGS and SNU-1), gastric cancer plasma
Expression Pattern	down-regulated
Function Description	Validation data showed MEF2C-AS1 and FENDRR were significantly downregulated in tumor tissues compared with normal tissues. And decreased FENDRR are associated with aggressive tumor characteristics including more advanced stage (P = .030), poor differentiation (P = .043) and lymphatic metastasis (P = .001). The expression level MEF2C-AS1 was significantly lower in DGC patients' plasma than that in healthy controls' plasma. In gastric cancer cell lines, knock-down of MEF2C-AS1 or FENDRR reduced the protein levels of FAT3, NTN1 and LYVE1 (the co-expressed genes), which were related with gastric cancer cell proliferation and invasion by previous studies. In addition, knock-down of MEF2C-AS1 or FENDRR promoted aggressive tumor behaviors in in-vitro assays.
Pubmed ID	30005210
Year	2018
Title	Characterization of Long Non-Coding RNAs and MEF2C-AS1 Identified as a Novel Biomarker in Diffuse Gastric Cancer

External Links